Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruixue Wang

Showing results (361-370 of 370) with videos related to

Pageof 37
Sort By:
You have reached the last page of results.This site can display upto 370 results.
American Journal of Cancer Research|May 9, 2018
A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft modelsRuixue Wang, Qinhuai Lai, Liangze Tang, et al.
Journal of Virology|January 18, 2019
Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect CellsRichard A Urbanowicz, Ruixue Wang, John E Schiel, et al.
Molecular Oncology|May 23, 2019
Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinomaYiran Tao, Ruixue Wang, Qinhuai Lai, et al.
European Journal of Medicinal Chemistry|May 14, 2020
Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studiesQinhuai Lai, Mengdan Wu, Ruixue Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 studyMichele Maio, Mayur M Amonkar, Josephine M Norquist, et al.
Cell Reports. Medicine|July 1, 2021
CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in miceNan Li, Madeline B Torres, Madeline R Spetz, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2021
Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimerJohnathan D Guest, Ruixue Wang, Khadija H Elkholy, et al.
Communications Biology|March 6, 2021
Engineering subtilisin proteases that specifically degrade active RASYingwei Chen, Eric A Toth, Biao Ruan, et al.
Journal of Virology|September 4, 2020
Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-NeutralizationBrian G Pierce, Zhen-Yong Keck, Ruixue Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Manish A Shah, Kei Muro, et al.
Pageof 37

Showing results (361-370 of 370) with videos related to

Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 370 results.
American Journal of Cancer Research|May 9, 2018
A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft modelsRuixue Wang, Qinhuai Lai, Liangze Tang, et al.
Journal of Virology|January 18, 2019
Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect CellsRichard A Urbanowicz, Ruixue Wang, John E Schiel, et al.
Molecular Oncology|May 23, 2019
Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinomaYiran Tao, Ruixue Wang, Qinhuai Lai, et al.
European Journal of Medicinal Chemistry|May 14, 2020
Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studiesQinhuai Lai, Mengdan Wu, Ruixue Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 studyMichele Maio, Mayur M Amonkar, Josephine M Norquist, et al.
Cell Reports. Medicine|July 1, 2021
CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in miceNan Li, Madeline B Torres, Madeline R Spetz, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2021
Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimerJohnathan D Guest, Ruixue Wang, Khadija H Elkholy, et al.
Communications Biology|March 6, 2021
Engineering subtilisin proteases that specifically degrade active RASYingwei Chen, Eric A Toth, Biao Ruan, et al.
Journal of Virology|September 4, 2020
Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-NeutralizationBrian G Pierce, Zhen-Yong Keck, Ruixue Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Manish A Shah, Kei Muro, et al.
Pageof 37